tetano
Editor, Senior Moderator
Commun Biol
. 2021 Feb 12;4(1):197.
doi: 10.1038/s42003-021-01736-8.
Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection
Philippe Karoyan[SUP] 1 2 3 [/SUP], Vincent Vieillard[SUP] 4 [/SUP], Luis G?mez-Morales[SUP] 5 6 [/SUP], Estelle Odile[SUP] 5 6 [/SUP], Am?lie Guihot[SUP] 7 8 [/SUP], Charles-Edouard Luyt[SUP] 9 [/SUP], Alexis Denis[SUP] 10 [/SUP], Pascal Grondin[SUP] 10 [/SUP], Olivier Lequin[SUP] 5 [/SUP]
Affiliations
Abstract
In light of the recent accumulated knowledge on SARS-CoV-2 and its mode of human cells invasion, the binding of viral spike glycoprotein to human Angiotensin Converting Enzyme 2 (hACE2) receptor plays a central role in cell entry. We designed a series of peptides mimicking the N-terminal helix of hACE2 protein which contains most of the contacting residues at the binding site, exhibiting a high helical folding propensity in aqueous solution. Our best peptide-mimics are able to block SARS-CoV-2 human pulmonary cell infection with an inhibitory concentration (IC[SUB]50[/SUB]) in the nanomolar range upon binding to the virus spike protein with high affinity. These first-in-class blocking peptide mimics represent powerful tools that might be used in prophylactic and therapeutic approaches to fight the coronavirus disease 2019 (COVID-19).
. 2021 Feb 12;4(1):197.
doi: 10.1038/s42003-021-01736-8.
Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection
Philippe Karoyan[SUP] 1 2 3 [/SUP], Vincent Vieillard[SUP] 4 [/SUP], Luis G?mez-Morales[SUP] 5 6 [/SUP], Estelle Odile[SUP] 5 6 [/SUP], Am?lie Guihot[SUP] 7 8 [/SUP], Charles-Edouard Luyt[SUP] 9 [/SUP], Alexis Denis[SUP] 10 [/SUP], Pascal Grondin[SUP] 10 [/SUP], Olivier Lequin[SUP] 5 [/SUP]
Affiliations
- PMID: 33580154
- DOI: 10.1038/s42003-021-01736-8
Abstract
In light of the recent accumulated knowledge on SARS-CoV-2 and its mode of human cells invasion, the binding of viral spike glycoprotein to human Angiotensin Converting Enzyme 2 (hACE2) receptor plays a central role in cell entry. We designed a series of peptides mimicking the N-terminal helix of hACE2 protein which contains most of the contacting residues at the binding site, exhibiting a high helical folding propensity in aqueous solution. Our best peptide-mimics are able to block SARS-CoV-2 human pulmonary cell infection with an inhibitory concentration (IC[SUB]50[/SUB]) in the nanomolar range upon binding to the virus spike protein with high affinity. These first-in-class blocking peptide mimics represent powerful tools that might be used in prophylactic and therapeutic approaches to fight the coronavirus disease 2019 (COVID-19).